SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 76923.00
87.22 (0.11%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
91	Gujarat Kidney And Super Speciality Ltd.	Q V PT	1,004 Small Cap	127.50 (0.08%)	101.45	4.08	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
92	Blue Jet Healthcare Ltd.	Q V PT	10,906 Small Cap	577 (0.14%)	44.01	5.05	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
93	Fabtech Technologies Ltd.	Q V PT	661 Small Cap	147.85 (-0.54%)	19.17	1.69	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
94	Sanofi Consumer Healthcare India Ltd.	Q V+ PT	10,773 Small Cap	4,692 (0.30%)	41.77	23.84	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
95	Laxmi Dental Ltd.	Q V PT	1,198 Small Cap	217.15 (-0.41%)	72.96	4.85	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
96	Fortis Healthcare Ltd.	Q V+ PT	71,140 Mid Cap	941.95 (-0.04%)	308.84	7.71	23.15	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
97	Suven Life Sciences Ltd.	Q V+ PT	8,807 Small Cap	297.85 (-4.44%)	N/A	5.02	-14.30	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
98	Narayana Hrudayalaya Ltd.	Q V PT	41,974 Mid Cap	2,070.10 (0.79%)	52.1	9.25	25.04	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
99	Wockhardt Ltd.	Q V+ PT	30,311 Small Cap	1,855.05 (-0.55%)	142.31	6.15	4.49	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
100	Orchid Pharma Ltd.	Q V PT	5,002 Small Cap	986.40 (0.01%)	110.65	3.65	13.89	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
101	Healthcare Global Enterprises Ltd.	Q V+ PT	10,110 Small Cap	679.05 (0.28%)	693.42	6.3	13.15	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
102	Park Medi World Ltd.	Q V+ PT	12,060 Small Cap	279.20 (0.00%)	329.35	14.02	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
103	Krsnaa Diagnostics Ltd.	Q V+ PT	1,758 Small Cap	536.65 (-0.98%)	17.33	1.79	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
104	Senores Pharmaceuticals Ltd.	Q V+ PT	6,500 Small Cap	1,317.55 (-6.66%)	349.68	8.67	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
105	Fermenta Biotech Ltd.	Q V PT	1,307 Small Cap	443 (-0.23%)	20.33	3.11	3.85	-0.38	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
106	Aurobindo Pharma Ltd.	Q V+ PT	89,115 Mid Cap	1,552.90 (0.26%)	36.9	3.92	-3.95	-0.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
107	Strides Pharma Science Ltd.	Q V+ PT	9,623 Small Cap	1,055.20 (1.07%)	52.4	2.93	3.25	-0.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
108	Hikal Ltd.	Q V+ PT	2,739 Small Cap	219.10 (-1.35%)	N/A	2.28	4.29	-1.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
109	Tarsons Products Ltd.	Q V+ PT	1,707 Small Cap	310 (-3.40%)	75.35	2.53	12.30	-1.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
110	Laurus Labs Ltd.	Q V+ PT	92,623 Mid Cap	1,745.85 (1.84%)	84.7	16.43	7.19	-2.25	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
111	Cohance Lifesciences Ltd.	Q V+ PT	16,444 Small Cap	429.15 (-0.15%)	91.75	4.2	7.51	-3.15	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
112	Granules India Ltd.	Q V+ PT	20,878 Small Cap	843 (0.05%)	51.82	5.09	2.07	-5.88	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
113	Piramal Pharma Ltd.	Q V PT	25,569 Small Cap	188.40 (-1.90%)	36.53	3.17	10.23	-6.64	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
114	Sanofi India Ltd.	Q V PT	7,760 Small Cap	3,383.70 (0.43%)	25.05	9.95	-8.74	-7.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
115	Alembic Pharmaceuticals Ltd.	Q V+ PT	16,009 Small Cap	821.70 (0.89%)	23.73	2.82	6.37	-8.79	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
116	Shilpa Medicare Ltd.	Q V+ PT	12,144 Small Cap	605 (-2.56%)	49.91	4.69	7.22	-12.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
117	Biocon Ltd.	Q V PT	71,063 Mid Cap	433.40 (-0.61%)	1910.29	2.6	2.96	-18.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
118	Dishman Carbogen Amcis Ltd.	Q V+ PT	2,922 Small Cap	184 (-1.26%)	29.98	0.44	5.82	-33.01	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
119	Jubilant Pharmova Ltd.	Q V+ PT	15,582 Small Cap	960 (-1.87%)	783	6.74	-24.99	-38.93	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
120	Suraksha Diagnostic Ltd.	Q V PT	1,300 Small Cap	249 (-0.28%)	40.4	5.31	9.86	-51.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Onesource Specialty	1,744.75	3.26%
Dr. Agarwals Health	487.60	2.53%
Metropolis Health.	590.30	2.17%
Laurus Labs	1,745.85	1.84%
Cipla	1,434.80	1.77%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Acutaas Chemicals	3,121.05	-7.35%
Senores Pharmaceutic	1,317.55	-6.66%
Suven Life Sciences	297.85	-4.44%
Wanbury	318.55	-3.82%
Panacea Biotec	418.10	-3.51%

News about Top Pharma Companies in India

Jul, 2026

Senores Pharmaceutic - Quaterly Results

The turnover zoomed to Rs. 269.90 millions, up 67.33% for the June 2026 quarter as against Rs. 161.30 millions during the year-ago period.Net Profit of the company move down -61.85% to Rs. 10.30 millions from Rs. 27.00 millions in the same quarter last year.The company reported a degrowth in operating Profit to 72.20 millions from 72.30 millions.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	269.90	161.30	67.33	269.90	161.30	67.33	1060.90	385.40	175.27
Other Income	95.50	120.80	-20.94	95.50	120.80	-20.94	663.50	219.90	201.73
PBIDT	72.20	72.30	-0.14	72.20	72.30	-0.14	476.70	147.10	224.07
Interest	22.20	17.60	26.14	22.20	17.60	26.14	69.80	65.20	7.06
PBDT	50.00	54.70	-8.59	50.00	54.70	-8.59	406.90	81.90	396.83
Depreciation	36.10	18.80	92.02	36.10	18.80	92.02	132.30	30.80	329.55
PBT	13.90	35.90	-61.28	13.90	35.90	-61.28	274.60	51.10	437.38
TAX	3.60	8.90	-59.55	3.60	8.90	-59.55	72.10	14.20	407.75
Deferred Tax	0.50	5.00	-90.00	0.50	5.00	-90.00	-12.40	-0.30	4033.33
PAT	10.30	27.00	-61.85	10.30	27.00	-61.85	202.50	36.90	448.78
Equity	460.54	460.54	0.00	460.54	460.54	0.00	460.50	460.50	0.00
PBIDTM(%)	26.75	44.82	-40.32	26.75	44.82	-40.32	44.93	38.17	17.73

Jul, 2026

Aurobindo Pharma moves up on entering into non-exclusive voluntary licensing agreement with MSD

Aurobindo Pharma is among a select group of global generic manufacturers to have signed this agreement

Jul, 2026

Aurobindo Pharma enters into non-exclusive voluntary licensing agreement with MSD

Aurobindo Pharma is among a select group of global generic manufacturers to have signed this agreement

Jul, 2026

Laurus Labs - Quaterly Results

The company witnessed a 22.64% growth in the revenue at Rs. 17571.60 millions for the quarter ended June 2026 as compared to Rs. 14327.50 millions during the year-ago period.Profit for the quarter ended June 2026 rises by 83.59% to Rs. 2899.60 millions from Rs. 1579.40 millions.Operating profit for the quarter ended June 2026 rose to 5191.30 millions as compared to 3489.00 millions of corresponding quarter ended June 2025.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	17571.60	14327.50	22.64	17571.60	14327.50	22.64	60890.70	52169.80	16.72
Other Income	200.70	215.20	-6.74	200.70	215.20	-6.74	774.30	1004.70	-22.93
PBIDT	5191.30	3489.00	48.79	5191.30	3489.00	48.79	15156.90	10448.00	45.07
Interest	352.00	438.90	-19.80	352.00	438.90	-19.80	1429.60	1822.00	-21.54
PBDT	4839.30	3050.10	58.66	4839.30	3050.10	58.66	13727.30	8626.00	59.14
Depreciation	957.60	935.70	2.34	957.60	935.70	2.34	3786.40	3587.90	5.53
PBT	3881.70	2114.40	83.58	3881.70	2114.40	83.58	9940.90	5038.10	97.31
TAX	982.10	535.00	83.57	982.10	535.00	83.57	2536.10	1234.20	105.49
Deferred Tax	-50.40	-61.60	-18.18	-50.40	-61.60	-18.18	-315.10	-304.20	3.58
PAT	2899.60	1579.40	83.59	2899.60	1579.40	83.59	7404.80	3803.90	94.66
Equity	1080.50	1079.60	0.08	1080.50	1079.60	0.08	1079.70	1078.50	0.11
PBIDTM(%)	29.54	24.35	21.32	29.54	24.35	21.32	24.89	20.03	24.29

Jul, 2026

Gujarat Kidney and Super Specialty submit notice of postal ballot.

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Gujarat Kidney and Super Specialty has enclosed the clippings of newspaper publication in respect of the Notice of Postal Ballot, published in the following newspapers on Thursday, July 23, 2026: The Financial Express-English (Ahmedabad edition); Gujarat Mitra- Gujarati (Vadodara Edition).

The above information is a part of company's filings submitted to BSE.

Jul, 2026

Sanofi India informs about analyst meet

Sanofi India has informed that the Company will hold an investor / analysts call for an update on Unaudited Financial Results for the quarter and half year ended 30th June 2026, the details enclosed.

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Max Healthcare Institute Ltd.	1,08,476 Crore
2	Yatharth Hospital & Trauma Care Services Ltd.	8,132 Crore
3	3B Blackbio Dx Ltd.	1,112 Crore
4	Artemis Medicare Services Ltd.	4,408 Crore
5	Novartis India Ltd.	4,023 Crore
6	Jupiter Life Line Hospitals Ltd.	10,728 Crore
7	Jagsonpal Pharmaceuticals Ltd.	1,511 Crore
8	Neuland Laboratories Ltd.	24,345 Crore
9	Kwality Pharmaceuticals Ltd.	2,815 Crore
10	Rainbow Childrens Medicare Ltd.	15,076 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	27,893	59,102	38.08	12.45	26.07	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,922	1,90,832	88.21	22.69	45.79	29.04
Lupin Ltd. (M)	Somewhat Good	2,405	1,10,189	20.66	4.92	11.95	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,358	42,278	40.04	9.35	27.05	25.35
Alkem Laboratories Ltd. (M)	Very Good	5,631	67,124	30.72	4.80	22.28	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,746	92,623	105
Sai Life Sciences Ltd. (S)	Very Good	1,291	27,347	53.73
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,922	1,90,832	39.27
Aurobindo Pharma Ltd. (M)	Very Good	1,553	89,115	38.01
Lupin Ltd. (M)	Somewhat Good	2,405	1,10,189	23.52
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,291	27,347	80.08	10.90	42.11	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,358	42,278	40.04	9.35	27.05	13.54
Mankind Pharma Ltd. (M)	Very Good	2,587	1,05,357	51.71	6.44	32.38	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,523	21.93	4.25	13.45	13.52
Lupin Ltd. (M)	Somewhat Good	2,405	1,10,189	20.66	4.92	11.95	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,405	1,10,189	20.66	4.92	11.95	32.37
Abbott India Ltd. (M)	Very Good	27,893	59,102	38.08	12.45	26.07	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,146	96,063	29.81	2.52	15.31	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,523	21.93	4.25	13.45	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,984	4,73,509	41.25	5.67	23.65	14.41

You have 9 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Senores Pharmaceutic - Quaterly Results

Aurobindo Pharma moves up on entering into non-exclusive voluntary licensing agreement with MSD

Aurobindo Pharma enters into non-exclusive voluntary licensing agreement with MSD

Laurus Labs - Quaterly Results

Gujarat Kidney and Super Specialty submit notice of postal ballot.

Sanofi India informs about analyst meet

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.